Article
Immunology
Ennio Giulio Favalli, Gilberto Cincinelli, Sabino Germinario, Raffaele Di Taranto, Francesco Orsini, Gabriella Maioli, Martina Biggioggero, Matteo Ferrito, Roberto Caporali
Summary: This study evaluated the impact of EMA recommendations on the prescription of JAK inhibitors (JAKis) and the use of the Expanded Risk Score in RA (ERS-RA) to quantify the risk of major adverse cardiac events (MACE) in patients with rheumatoid arthritis (RA). A large proportion of RA patients were classified as ineligible for JAKis according to EMA criteria, with increased MACE risk being the most common reason. The use of ERS-RA method significantly reduced the rate of patients with increased cardiovascular risk.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Lilla Toth, Mark F. Juhasz, Laszlo Szabo, Alan Abada, Fruzsina Kiss, Peter Hegyi, Nelli Farkas, Gyoergy Nagy, Zsuzsanna Helyes
Summary: JAK inhibitors have been shown to be effective in treating rheumatoid arthritis (RA) by reducing joint inflammation and providing direct analgesic effect. This meta-analysis provides comprehensive evidence of the superiority of JAK inhibitors in improving patient-reported outcomes and disease activity indices in RA.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Kim Lauper, Kimme L. Hyrich
Summary: Trials of JAK-inhibitors have demonstrated efficacy in treating rheumatoid arthritis, but real-world studies evaluating their effectiveness are currently limited, especially for certain molecules. More high-quality studies are needed to assess the real-world effectiveness of JAK-inhibitors comprehensively.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Ludovico De Stefano, Emanuele Bozzalla Cassione, Francesca Bottazzi, Elena Marazzi, Francesco Maggiore, Valentina Morandi, Carlomaurizio Montecucco, Serena Bugatti
Summary: The study evaluates the real-life effectiveness of JAKis in improving pain in patients with rheumatoid arthritis. The results demonstrate good efficacy of JAKis in pain relief, especially in patients with lower disease activity.
INTERNAL AND EMERGENCY MEDICINE
(2023)
Review
Medicine, General & Internal
Robert Harrington, Patricia Harkins, Richard Conway
Summary: This article reviews the key findings of the most impactful cohort of studies and registry data since the ORAL Surveillance study and evaluates the role of JAKis in practice and how to determine the suitability of patients for JAKi use.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Chemistry, Medicinal
Eric Toussirot
Summary: Current pharmacological treatments for axSpA are limited and often unsatisfactory, necessitating the development of new options. The JAK-STAT pathway plays a crucial role in the pathogenesis of axSpA, making JAK inhibitors a potential treatment option. This review examines the role of JAK-STAT signaling in axSpA and summarizes recent clinical trial results of JAK inhibitors in patients with the condition.
Article
Medicine, General & Internal
Jumpei Temmoku, Kiyoshi Migita, Shuhei Yoshida, Haruki Matsumoto, Yuya Fujita, Naoki Matsuoka, Makiko Yashiro-Furuya, Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Hiroshi Watanabe, Masayuki Miyata
Summary: In this retrospective cohort study, the retention rates and effectiveness of biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (JAKi) were compared in elderly patients with RA. The study found that there was no significant difference in the drug retention rates and clinical response between the two treatment groups, suggesting that elderly patients with RA can achieve similar clinical improvement with bDMARDs or JAKi.
Article
Rheumatology
Calin D. Popa, Merel A. A. Opdam, Nathan den Broeder, Hanne van Ballegooijen, Kelly Mulder, Kayleigh M. van de Wiel, Noortje van Herwaarden, Maike H. M. Wientjes, Alfons A. den Broeder
Summary: A comparison study on RA patients in the Netherlands showed that the risk of cardiovascular events was not significantly different between JAKi users and bDMARDs users, although a slight increase in risk cannot be ruled out in certain high-risk patients.
Article
Pharmacology & Pharmacy
Yun-Kyoung Song, Gaeun Lee, Jinseub Hwang, Ji-Won Kim, Jin-Won Kwon
Summary: In Korean patients with rheumatoid arthritis (RA) without cardiovascular disease (CVD), Janus kinase (JAK) inhibitors were not associated with major adverse cardiovascular events (MACEs) compared to biologic disease-modifying antirheumatic drugs (bDMARDs).
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Cecile Philippoteaux, Valentine Deprez, Aurore Nottez, Emeline Cailliau, Eric Houvenagel, Xavier Deprez, Peggy Philippe, Tristan Pascart, Rene-Marc Flipo, Vincent Goeb, Jean-Guillaume Letarouilly
Summary: This study compared the baseline characteristics of rheumatoid arthritis (RA) patients initiating Baricitinib (BARI) or Tofacitinib (TOFA) before and after the European Medicine Agency (EMA) issued warnings on venous thromboembolism (VTE) risk. The study also compared the real-world persistence with these two drugs. The results showed no significant change in patient characteristics after the EMA's warnings, but a lower proportion of VTE history was observed in patients initiating the drugs after May 2019.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Rheumatology
Francesco Campanaro, Andrea Zaffaroni, Elettra Cacioppo, Antonella Cappelli, Lorenza Bertu, Marco Paolo Donadini, Alessandro Squizzato, Alberto Batticciotto
Summary: A systematic review showed that the use of Janus kinase inhibitors (JAKi) for the treatment of immune-mediated inflammatory diseases (IMIDs) does not increase the risk of thrombosis compared with placebo.
Review
Biochemistry & Molecular Biology
Przemyslaw J. Kotyla, Malgorzata Engelmann, Joanna Giemza-Stoklosa, Bartosz Wnuk, Md Asiful Islam
Summary: Recent advances in immunology have led to the characterization of signal transmitting pathways, among which Janus kinases are essential components. While JAK inhibitors have shown efficacy in treating leukemia and rheumatological disorders, they may also increase the risk of venous thrombosis in patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Monika Czokolyova, Attila Hamar, Anita Pusztai, Gabor Tajti, Edit Vegh, Zsofia Petho, Nora Bodnar, Agnes Horvath, Boglarka Soos, Szilvia Szamosi, Anita Szentpeteri, Ildiko Seres, Mariann Harangi, Gyorgy Paragh, Gyorgy Kerekes, Levente Bodoki, Andrea Domjan, Katalin Hodosi, Tamas Seres, Gyorgy Panyi, Zoltan Szekanecz, Gabriella Szucs
Summary: The study found that tofacitinib treatment had balanced effects on lipids and other metabolic markers in patients with rheumatoid arthritis (RA). Various correlations were observed between lipids, clinical markers, and vascular pathophysiology in relation to tofacitinib treatment. Complex assessment of these factors could be used in clinical practice to monitor cardiovascular status and treatment response in RA patients.
Review
Immunology
Rongxiu Huo, Xinxiang Huang, Yang Yang, Jinying Lin
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by cytokine imbalance. Dysregulation of the JAK/STAT pathway plays a role in SLE pathogenesis. JAK inhibitors (JAKis) show promise in reducing corticosteroid and immunosuppressant use in SLE treatment. Clinical trials are ongoing, and JAKis may improve traditional treatment strategies for SLE.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Review
Pharmacology & Pharmacy
S. Sajith Kumar, Madhumitha Haridoss, Krishnamurthy Venkataraman, Bhavani Shankara Bagepally
Summary: This study found that Janus kinase inhibitors (JAK-i) are cost-effective as a second-line treatment for rheumatoid arthritis (RA) after csDMARD failure, but not cost-effective after csDMARD-TNF-a-i failure.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Rheumatology
Winnie M. Y. Chen, Sujith Subesinghe, Sara Muller, Samantha L. Hider, Christian D. Mallen, Ian C. Scott
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2020)
Correction
Rheumatology
Annabelle R. Machin, Opeyemi Babatunde, Randula Haththotuwa, Ian Scott, Milica Blagojevic-Bucknall, Nadia Corp, Carolyn A. Chew-Graham, Samantha L. Hider
CLINICAL RHEUMATOLOGY
(2020)
Review
Rheumatology
Annabelle R. Machin, Opeyemi Babatunde, Randula Haththotuwa, Ian Scott, Milica Blagojevic-Bucknall, Nadia Corp, Carolyn A. Chew-Graham, Samantha L. Hider
CLINICAL RHEUMATOLOGY
(2020)
Article
Rheumatology
Ian C. Scott, Gareth McCray, Gillian Lancaster, Nadine E. Foster, Jonathan C. Hill
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2020)
Article
Rheumatology
Ian C. Scott, James Bailey, Chris White, Christian D. Mallen, Sara Muller
Summary: This study found that opioid prescribing is common in the management of inflammatory arthritis (IA) pain, despite limited evidence of efficacy and potential harms.
Article
Orthopedics
Zoe Paskins, Laurna Bullock, Fay Manning, Simon Bishop, Paul Campbell, Elizabeth Cottrell, G. P. Partner, Clare Jinks, Melanie Narayanasamy, Ian C. Scott, Opinder Sahota, Sarah Ryan
Summary: This study aimed to explore the acceptability of and preferences for remote consultations among patients with osteoporosis and rheumatoid arthritis. The findings show that attitudes towards remote consultations, views on fairness and intervention coherence varied depending on the patients' consultation needs and their perceptions of the pandemic.
BMC MUSCULOSKELETAL DISORDERS
(2022)
Article
Genetics & Heredity
Kazuyoshi Ishigaki, Saori Sakaue, Chikashi Terao, Yang Luo, Kyuto Sonehara, Kensuke Yamaguchi, Tiffany Amariuta, Chun Lai Too, Vincent A. Laufer, Ian C. Scott, Sebastien Viatte, Meiko Takahashi, Koichiro Ohmura, Akira Murasawa, Motomu Hashimoto, Hiromu Ito, Mohammed Hammoudeh, Samar Al Emadi, Basel K. Masri, Hussein Halabi, Humeira Badsha, Imad W. Uthman, Xin Wu, Li Lin, Ting Li, Darren Plant, Anne Barton, Gisela Orozco, Suzanne M. M. Verstappen, John Bowes, Alexander J. MacGregor, Suguru Honda, Masaru Koido, Kohei Tomizuka, Yoichiro Kamatani, Hiroaki Tanaka, Eiichi Tanaka, Akari Suzuki, Yuichi Maeda, Kenichi Yamamoto, Satoru Miyawaki, Gang Xie, Jinyi Zhang, Christopher Amos, Edward Keystone, Gertjan Wolbink, Irene Van der Horst-Bruinsma, Jing Cui, Katherine P. Liao, Robert J. Carroll, Hye-Soon Lee, So-Young Bang, Katherine A. Siminovitch, Niek de Vries, Lars Alfredsson, Solbritt Rantapaa-Dahlqvist, Elizabeth W. Karlson, Sang-Cheol Bae, Robert P. Kimberly, Jeffrey C. Edberg, Xavier Mariette, Tom Huizinga, Philippe Dieude, Matthias Schneider, Martin Kerick, Joshua C. Denny, Koichi Matsuda, Keitaro Matsuo, Tsuneyo Mimori, Fumihiko Matsuda, Keishi Fujio, Yoshiya Tanaka, Atsushi Kumanogoh, Matthew Traylor, Cathryn M. Lewis, Stephen Eyre, Huji Xu, Richa Saxena, Thurayya Arayssi, Yuta Kochi, Katsunori Ikari, Masayoshi Harigai, Peter K. Gregersen, Kazuhiko Yamamoto, S. Louis Bridges, Leonid Padyukov, Javier Martin, Lars Klareskog, Yukinori Okada, Soumya Raychaudhuri
Summary: This study conducted multi-ancestry genome-wide association analyses and identified 124 risk loci for rheumatoid arthritis, of which 34 are novel. The fine-mapping analysis revealed potential causal variants and improved the genetic predictability of rheumatoid arthritis.
Article
Rheumatology
Ian C. Scott, Rebecca Whittle, James Bailey, Helen Twohig, Samantha L. Hider, Christian D. Mallen, Sara Muller, Kelvin P. Jordan
Summary: Despite little evidence, there is widespread use of analgesics in patients with inflammatory arthritis. A comprehensive evaluation of analgesic prescribing from 2004 to 2020 revealed a decline in prescription rates, but they remained common. The specific prescribing patterns varied based on different factors.
Article
Health Care Sciences & Services
Ian C. Scott, Rebecca Whittle, James Bailey, Helen Twohig, Samantha L. Hider, Christian D. Mallen, Sara Muller, Kelvin P. Jordan
Summary: This study updated algorithms for diagnosing RA, PsA, and axial SpA in primary care and used electronic health record data to describe their incidence and prevalence in England. The findings showed an increasing prevalence of RA and PsA, while the prevalence of axial SpA fluctuated. The annual incidence of these diseases also varied over time, with an increase following the publication of new classification criteria. The COVID-19 pandemic had a significant impact on the diagnosis of these diseases, leading to a decrease in their incidence in 2020.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Rheumatology
Fowzia Ibrahim, Margaret Ma, David L. Scott, Ian C. Scott
Summary: This study evaluated the relationship between pain intensity and disease activity in rheumatoid arthritis (RA) patients. It found that pain intensity is associated with disease activity and particularly with patient global assessments. There is some discordance between pain intensity and disease activity, and temporal changes in disease activity are closely related to changes in pain intensity.
ARTHRITIS RESEARCH & THERAPY
(2022)
Letter
Rheumatology
Ahmed B. Tarar, Jake Weddell, Fay Manning, Shouma Dutta, Zoe Paskins, Ian C. Scott
RHEUMATOLOGY ADVANCES IN PRACTICE
(2021)
Meeting Abstract
Rheumatology
Ian C. Scott, Ram Bajpai, Samantha L. Hider, Toby Helliwell, Sara Muller, Christian D. Mallen
Meeting Abstract
Rheumatology
Ian C. Scott, James Bailey, Christopher White, Christian D. Mallen, Sara Muller
Meeting Abstract
Rheumatology
Ian C. Scott, Gareth McCray, Gillian Lancaster, Nadine E. Foster, Jonathan C. Hill
Article
Rheumatology
Ian C. Scott, Julie Mount, Jane Barry, Bruce Kirkham